These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 24143077

  • 1. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.
    Cazzola M, Segreti A, Matera MG.
    Drug Des Devel Ther; 2013; 7():1201-8. PubMed ID: 24143077
    [Abstract] [Full Text] [Related]

  • 2. Umeclidinium/vilanterol fixed-dose combination for COPD.
    Gras J.
    Drugs Today (Barc); 2014 Mar; 50(3):231-8. PubMed ID: 24696868
    [Abstract] [Full Text] [Related]

  • 3. Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review.
    Ramadan WH, Al Masri S, Rizk J.
    Clin Respir J; 2019 Nov; 13(11):663-673. PubMed ID: 31389190
    [Abstract] [Full Text] [Related]

  • 4. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
    Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov; 14():1251-1265. PubMed ID: 31239659
    [Abstract] [Full Text] [Related]

  • 5. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG.
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [Abstract] [Full Text] [Related]

  • 6. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.
    Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
    Vogelmeier CF, Jones PW, Kerwin EM, Boucot IH, Maltais F, Tombs L, Compton C, Lipson DA, Bjermer LH.
    Respir Res; 2021 Oct 28; 22(1):279. PubMed ID: 34711232
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 28; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 10. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G, Walker RR, Brooks J, Mehta R, Crater G.
    Pulm Pharmacol Ther; 2012 Dec 28; 25(6):465-71. PubMed ID: 22955035
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
    Donohue JF, Singh D, Munzu C, Kilbride S, Church A.
    Respir Med; 2016 Mar 28; 112():65-74. PubMed ID: 26797016
    [Abstract] [Full Text] [Related]

  • 15. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
    Blair HA, Deeks ED.
    Drugs; 2015 Jan 28; 75(1):61-74. PubMed ID: 25398674
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
    Rhee CK, Yoshisue H, Lad R.
    Adv Ther; 2019 Mar 28; 36(3):495-519. PubMed ID: 30742242
    [Abstract] [Full Text] [Related]

  • 18. Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials.
    Zhai C, Wang F, Xu R, Sun X, Ma W, Wang L.
    Postgrad Med J; 2024 Sep 22; 100(1188):721-729. PubMed ID: 38652265
    [Abstract] [Full Text] [Related]

  • 19. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
    Malerba M, Nardin M, Santini G, Mores N, Radaeli A, Montuschi P.
    Ther Adv Respir Dis; 2018 Sep 22; 12():1753466618760779. PubMed ID: 29537340
    [Abstract] [Full Text] [Related]

  • 20. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P, Worsley S, Singh D, Román-Rodríguez M, Newby DE, Müllerová H.
    Int J Chron Obstruct Pulmon Dis; 2016 Sep 22; 11():2885-2895. PubMed ID: 27932872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.